Pharmacological approaches to smoking cessation.
Currently, 28% of U.S. adults smoke, and this percentage is declining by 0.5% per year; however, this rate of decline must double if the goal in Healthy People 2000 (smoking prevalence of no more than 15% among adults) is to be reached. To help decrease physiological barriers to smoking cessation, numerous pharmacological approaches have been used. I review the effectiveness of these approaches, including interventions reported in the relatively older literature as well as more recent approaches, such as nicotine replacement, clonidine, antianxiety agents, and antidepressants. I also discuss the results and design of clinical trials.
Robbins
A S
AS
Department of Public Health and Preventive Medicine, Loma Linda University, CA 92350.
D000279:Administration, Cutaneous; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D002065:Buspirone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003000:Clonidine / Q000627:therapeutic use; D004311:Double-Blind Method; D006801:Humans; D009538:Nicotine / Q000008:administration & dosage / Q000627:therapeutic use; D016540:Smoking Cessation / Q000379:methods*; D000074606:Smoking Prevention
D000928:Antidepressive Agents; D009538:Nicotine; D003000:Clonidine; D002065:Buspirone